中轴型脊柱关节炎患者缓解的预测因素:一项系统文献综述
该系统文献综述检索了MEDLINE、EMBASE和Cochrane CENTRAL(自建库至2022年5月20日)及2020-2021年ACR和EULAR会议摘要,纳入21篇通过多因素分析探讨缓解预后因素的随机对照试验和队列研究。最一致的缓解预测因素包括较年轻年龄、HLA-B27阳性、男性、较低基线BASDAI、较低基线BASFI、较低基线ASDAS-C反应蛋白、TNFi治疗及联合使用csDMARDs;但许多预测因素仅见于1-2项研究,需进一步设计良好的预后研究确认。
要点
- 最一致的缓解预测因素包括较年轻年龄、HLA-B27阳性、男性、较低基线BASDAI、较低基线BASFI、较低基线ASDAS-C反应蛋白、TNFi治疗及联合csDMARDs。
- 较短病程、较低HAQ-S评分及未使用过TNFi在两项研究中为缓解预测因素。
- 许多预测因素仅见于1-2项研究,研究设计存在差异,需进一步设计良好的预后研究确认。
核心结论
- 中轴型脊柱关节炎患者缓解的预测因素已被识别,但许多预测因素仅见于1-2项研究。
- 鉴于研究设计存在差异,需进一步设计良好的预后研究以确认这些预测因素并推广至一般中轴型脊柱关节炎人群。
研究设计与样本
- 系统文献综述,检索MEDLINE、EMBASE和Cochrane CENTRAL自建库至2022年5月20日,以及2020-2021年ACR和EULAR会议摘要。
- 纳入通过多因素分析探讨缓解预后因素的随机对照试验和队列研究,最终纳入来自4592条引文的21篇文章。
主要发现
- 3项研究探讨「持续缓解」(≥3次连续访视),其余研究评估「时点缓解」(单一时点,范围从12周至8年)。
- 最常用的缓解标准为ASDAS inactive disease(14项研究)和ASAS部分缓解标准(11项研究)。
- 最一致的缓解预测因素包括较年轻年龄、HLA-B27阳性、男性、较低基线BASDAI、较低基线BASFI、较低基线ASDAS-C反应蛋白、TNFi治疗及联合使用csDMARDs。
- 较短病程、较低HAQ-S评分及未使用过TNFi在两项研究中为缓解预测因素;其他因素仅在单项研究中被发现为缓解预测因素。
关键数值与推荐
- 持续缓解定义为≥3次连续访视。
- 时点缓解评估时间范围从12周至8年。
- 最常用缓解标准为ASDAS inactive disease(14项研究)和ASAS部分缓解标准(11项研究)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 许多预测因素仅见于1-2项研究。
- 研究设计存在差异。
- 需进一步设计良好的预后研究以确认这些预测因素并推广至一般中轴型脊柱关节炎人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Achievement of remission is a desirable outcome and the identification of predictors of remission may aid in the clinical management of axial spondyloarthritis (axSpA). Our aim was to summarise predictors of remission in people with axSpA. METHODS: In this systematic literature review (SLR), we searched MEDLINE, EMBASE, and Cochrane CENTRAL from their inception to May 20, 2022, and 2020-2021 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) meeting abstracts. We included randomized controlled trials and cohort studies in which prognostic factors associated with remission were investigated by multivariable analysis. RESULTS: The SLR comprised 21 articles from 4592 citations. Three studies investigated "sustained remission" (≥3 consecutive visits), while the other assessed "point remission" (at single points in time, varying from 12 weeks to 8 years). The most used remission criteria were Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (14 studies) and Assessment of SpondyloArthritis international Society partial remission criteria (11 studies). Younger age, HLA-B27 positivity, male gender, lower baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), lower baseline Bath Ankylosing Spondylitis Functional Index (BASFI), lower baseline ASDAS-C-reactive protein, treatment with tumour necrosis factor inhibitors (TNFi), and concomitant use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), were the most consistent predictors of remission. Additionally, shorter disease duration, lower Health Assessment Questionnaire for the spondyloarthropathies and TNFi naivety were predictors of remission in two studies. Other factors were found to be predictors of remission in one study only. CONCLUSIONS: Predictors of remission in axSpA were identified. However, many of these predictors were only identified in 1-2 studies. Considering the differences in study design, further well-designed prognostic studies are needed to confirm and allow generalisation of these predictors to the general axSpA population.
引用
- Pinto AS, Farisogullari B, Machado PM, et al. Predictors of remission in people with axial spondyloarthritis: A systematic literature review. Semin Arthritis Rheum. 2022. PMID: 35944350. doi:10.1016/j.semarthrit.2022.152078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。